Get the Stockscreener App
1.27
0.79%
0.01
Outlook Therapeutics Inc stock is traded at $1.27, with a volume of 496.69K.
It is up +0.79% in the last 24 hours and up +19.81% over the past month.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$1.26
Open:
$1.3
24h Volume:
496.69K
Relative Volume:
0.13
Market Cap:
$56.41M
Revenue:
-
Net Income/Loss:
$-51.50M
P/E Ratio:
-0.3175
EPS:
-4
Net Cash Flow:
$-47.10M
1W Performance:
-5.22%
1M Performance:
+19.81%
6M Performance:
-18.06%
1Y Performance:
-79.01%
1-Day Range:
$1.23
$1.30
1-Week Range:
$1.221
$1.37
52-Week Range:
$0.79
$6.98
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Name
Outlook Therapeutics Inc
Sector
Industry
Phone
(609) 619-3990
Address
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.27 | 55.97M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.52 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.42 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.79 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.21 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.05 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-25 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-02-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Mar-27-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-15-24 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-25-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-27-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Aug-31-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-31-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-30-23 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-30-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Aug-30-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Aug-30-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-13-23 | Initiated | CapitalOne | Overweight |
| Apr-03-23 | Initiated | Guggenheim | Buy |
| Feb-06-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-22 | Initiated | BTIG Research | Buy |
| Sep-13-22 | Initiated | Chardan Capital Markets | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| May-16-19 | Initiated | Oppenheimer | Outperform |
| Apr-22-19 | Initiated | Ascendiant Capital Markets | Buy |
View All
Outlook Therapeutics Inc Stock (OTLK) Latest News
Can Outlook Therapeutics Inc. stock beat analyst upgradesJuly 2025 Setups & Weekly High Return Forecasts - newser.com
Outlook Therapeutics (OTLK) Re-Submits BLA for Key Eye Treatment - GuruFocus
Outlook Therapeutics resubmits BLA for wet AMD treatment - Investing.com
How Outlook Therapeutics Inc. (41ON) stock compares with tech leadersQuarterly Profit Review & Stock Portfolio Risk Control - newser.com
How Outlook Therapeutics Inc. stock reacts to Fed rate cutsQuarterly Profit Report & Free Technical Confirmation Trade Alerts - newser.com
Outlook Therapeutics Resubmits Biologics License Application for ONS-5010 to FDA for Wet AMD Treatment - Quiver Quantitative
Outlook Therapeutics Inc. stock prediction for this weekBond Market & Capital Efficiency Focused Ideas - newser.com
Outlook Therapeutics (Nasdaq: OTLK) re-submits BLA for LYTENAVA in wet AMD - Stock Titan
Is Outlook Therapeutics Inc. (41ON) stock worth buying before Fed actionLayoff News & Risk Controlled Stock Pick Alerts - newser.com
Will Outlook Therapeutics Inc. (41ON) stock enhance shareholder valueEarnings Recap Report & AI Driven Stock Reports - newser.com
Is Outlook Therapeutics Inc. stock a smart buy before Fed meetingWeekly Volume Report & Weekly Market Pulse Updates - newser.com
Is Outlook Therapeutics Inc. stock cheap at current valuationTrade Risk Report & Daily Price Action Insights - newser.com
What earnings margins imply for Outlook Therapeutics Inc. (41O) stockMarket Rally & Long-Term Growth Stock Strategies - newser.com
Outlook Therapeutics Inc. stock momentum explainedMarket Activity Summary & Expert Verified Stock Movement Alerts - newser.com
Why analysts upgrade Outlook Therapeutics Inc. stockJuly 2025 PreEarnings & Long-Term Capital Growth Strategies - newser.com
Is Outlook Therapeutics Inc. (41O) stock bottoming after sell offTrade Volume Summary & Daily Chart Pattern Signals - newser.com
Is Outlook Therapeutics Inc. stock a dividend growth opportunityJuly 2025 Momentum & Risk Adjusted Swing Trade Ideas - newser.com
What technical models suggest about Outlook Therapeutics Inc.’s comebackWeekly Gains Summary & Real-Time Volume Spike Alerts - newser.com
What analysts say about Outlook Therapeutics Inc 41O stockResistance Zone Identification & Low Cost Wealth Strategies - earlytimes.in
Weiss Ratings Reiterates "Sell (D-)" Rating for Oncobiologics (NASDAQ:OTLK) - MarketBeat
Outlook Therapeutics Inc. stock chart pattern explainedMarket Growth Summary & Free Weekly Chart Analysis and Trade Guides - newser.com
What drives Chordate Medical Holding AB publ K1Z0 stock priceFlag and Pennant Patterns & Market Crushing Stock Picks - earlytimes.in
Will Outlook Therapeutics Inc. (41ON) stock outperform value peersJuly 2025 Retail & Risk Controlled Stock Pick Alerts - newser.com
How to read the order book for Outlook Therapeutics Inc.2025 Market Sentiment & Smart Investment Allocation Tips - newser.com
Full technical analysis of Outlook Therapeutics Inc. stockDip Buying & Fast Gain Swing Trade Alerts - newser.com
Is Outlook Therapeutics Inc. (41ON) stock testing key supportTrade Risk Assessment & Accurate Technical Buy Alerts - newser.com
What drives Outlook Therapeutics Inc 41ON stock priceREITs Market Trends & Rapid Portfolio Strategies - earlytimes.in
Outlook Therapeutics (OTLK) Price Target Increased by 11.90% to 9.59 - Nasdaq
Outlook Therapeutics Inc Stock (OTLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):